Compare CRTO & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRTO | EVO |
|---|---|---|
| Founded | 2005 | 1993 |
| Country | France | Germany |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2013 | 2021 |
| Metric | CRTO | EVO |
|---|---|---|
| Price | $19.58 | $3.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $38.44 | $7.00 |
| AVG Volume (30 Days) | ★ 662.2K | 222.7K |
| Earning Date | 02-04-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 83.79 | N/A |
| EPS | ★ 3.00 | N/A |
| Revenue | ★ $1,956,800,000.00 | $887,396,457.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.42 | $8.52 |
| P/E Ratio | $6.84 | ★ N/A |
| Revenue Growth | ★ 0.53 | N/A |
| 52 Week Low | $19.00 | $2.84 |
| 52 Week High | $47.27 | $4.80 |
| Indicator | CRTO | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 41.70 | 60.22 |
| Support Level | $20.00 | $3.58 |
| Resistance Level | $21.55 | $3.87 |
| Average True Range (ATR) | 0.83 | 0.08 |
| MACD | -0.04 | 0.04 |
| Stochastic Oscillator | 2.84 | 67.09 |
Criteo SA is an ad-tech company in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.